PBS drug touts complete response

A Phase 2 study has generated more evidence in favour of using GSK’s Jemperli to treat mismatch repair-deficient (dMMR) cancers, with data suggesting it can trigger complete tumour clearance, particularly in rectal cancer.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here